Dec 17, 2009 8:00 am EST SCYNEXIS, Inc. Receives Milestone Payment From Collaboration With Merck & Co., Inc.
Nov 3, 2009 8:03 am EST SCYNEXIS' SCY-635 Demonstrates Positive Antiviral Activity in Combination with Approved and Investigational Anti-HCV Agents
Oct 28, 2009 2:59 pm EDT SCYNEXIS to Present HCV Data on Novel Cyclophilin Inhibitor SCY-635 at AASLD Annual Meeting
Oct 27, 2009 8:00 am EDT SCYNEXIS Receives Milestone Payment in Oncology Collaboration with Merck & Co., Inc.
Jan 8, 2009 9:00 am EST First Candidate from SCYNEXIS' Novel Cyclophilin Inhibitor Platform, SCY-635, Establishes Proof of Concept in HCV-Infected Adults
Dec 11, 2008 9:00 am EST SCYNEXIS and DNDi Extend Collaboration to Identify Drug Candidates to Treat Sleeping Sickness
